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Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated malignancy with high prevalence in Southern
Chinese. In order to assess whether defects of EBV-specific immunity may contribute to the tumor, the phenotype and function
of circulating T-cells and tumor infiltrating lymphocytes (TILs) were investigated in untreated NPC patients. Circulating naı ¨ve
CD3
+CD45RA
+ and CD4
+CD25
2 cells were decreased, while activated CD4
+CD25
+ T-cells and CD3
2CD16
+ NK-cells were
increased in patients compared to healthy donors. The frequency of T-cells recognizing seven HLA-A2 restricted epitopes in
LMP1 and LMP2 was lower in the patients and remained low after stimulation with autologous EBV-carrying cells. TILs
expanded in low doses of IL-2 exhibited an increase of CD3
+CD4
+, CD3
+CD45RO
+ and CD4
+CD25
+ cells and 2 to 5 fold higher
frequency of LMP1 and LMP2 tetramer positive cells compared to peripheral blood. EBV-specific cytotoxicity could be
reactivated from the blood of most patients, whereas the TILs lacked cytotoxic activity and failed to produce IFNc upon specific
stimulation. Thus, EBV-specific rejection responses appear to be functionally inactivated at the tumor site in NPC.
Citation: Li J, Zeng X-H, Mo H-Y, Role ´n U, Gao Y-F, et al (2007) Functional Inactivation of EBV-Specific T-Lymphocytes in Nasopharyngeal Carcinoma:
Implications for Tumor Immunotherapy. PLoS ONE 2(11): e1122. doi:10.1371/journal.pone.0001122
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is an epithelial neoplasm that
occurs at low frequency worldwide (,1 case per 10
5 individuals/
year), but at a more than 100 fold higher frequency in South-East
Asia, North Africa and Alaska (30–80 cases per 10
5 individual/
year in Southern China) (reviewed in [1]. NPC can be categorized
into three histological types: Type I, keratinizing squamous-cell
carcinomas (SSC); Type II, non-keratinizing squamous carcinoma;
Type III, undifferentiated carcinoma, [2]. In North America 25%
of NPCs are histological Type I, 12% Type II, and 63% Type III,
while in Southern China the distribution is 2%, 3%, and 95%,
respectively. The pathogenesis of NPC is complex and both
genetic and environmental factors are believed to play important
roles [1,3]. In addition, the regular detection of Epstein Barr virus
(EBV) in the malignant cells of virtually all cases of NPC Type II
and Type III [4] suggests that the virus is a determinant factor in
oncogenesis.
EBV is a c-herpes virus that causes asymptomatic life-long
persistent infections in .90% of the adults population worldwide
and is associated with a variety of malignancies of lymphoid,
epithelial and mesenchimal cell origin including, in addition to
NPC, EBV Burkitt’s lymphoma (BL), NK/T cells lymphoma,
Hodgkin lymphoma (HD), immunoblastic lymphoma and lejo-
myosarcoma arising in immunosuppressed and HIV patients and
some histological types of gastric cancer (reviewed in [3,5]. The
malignant cells of these tumors sustain non productive EBV
infections characterized by the expression of a restricted set of viral
genes that, in different combinations, define three types of viral
latency. In latency I, seen in BL, only the EBERs and BARTs
transcripts and the EBV nuclear antigen (EBNA)-1 are expressed.
In latency II, seen in EBV positive HD and NPC, the latent
membrane proteins (LMP)-1 and -2 are expressed together with
the latency I products, while six EBV nuclear antigens (EBNA1-6),
LMP1 and -2 are expressed in latency III, seen in lymphoproli-
ferative disorders associated with immunosuppression. Type III
latency is also expressed in EBV immortalized lymphoblastoid cell
lines (LCLs) obtained by in vitro EBV infection of normal B-
lymphocytes or by spontaneous outgrowth from the blood of
virtually all EBV carriers.
Vigorous humoral and cellular immune responses control the
proliferation of EBV infected cells in healthy virus carriers. Both
non-specific, NK-cell mediated, and EBV-specific, T-cell mediat-
ed, responses were shown to play important roles during primary
infection (reviewed in [6], while EBV-specific T cells appear to be
critically involved in restraining the proliferation of EBV infected
cells during life-long persistent infection [7,8]. Recent data
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have confirmed that T cells specific for EBV antigens expressed
during latent and productive infection are maintained in the blood
of healthy carriers at relatively high frequencies throughout life
[9]. Direct evidence for the importance of these EBV-specific T
cells in controlling the oncogenic capacity of the virus is provided
by the occurrence of EBV associated immunoblastic lymphomas
in the patients where their activity is impaired by congenital
immunodiciency, immunosuppressive therapy or HIV infection
[10]. These EBV associated lymphomas can be prevented or even
cured by adoptive transfer of in vitro activated and expanded EBV-
specific T cells [11,12,13], suggesting that reconstitution of EBV-
specific immunity may be a useful strategy in the management of
EBV associated malignancies.
While the contribution of immunosuppression to the pathogen-
esis of immunoblastic lymphoma is well established, the failure of
EBV specific immunity in other EBV associated malignancies is
not well understood since the affected patients are usually fairly
immunocompetent. The capacity of the tumor cells to evade EBV
specific immunity has been proposed to play a role in the
pathogenesis of BLs since the tumor cells exhibit a non-
immunogenic phenotype and their viral antigen expression is
restricted to EBNA-1 that was shown to be a poor target for MHC
class I restricted rejection responses [14,15,16]. However, evidence
collected from both HD and NPC suggests that, in accordance
with their expression of immunogenic viral antigens, the malignant
cells of these tumors are efficiently recognized by EBV specific T
cell [17]. A selective impairment EBV specific responses was
demonstrated at the tumor site in EBV positive HD [18],
suggesting that local modulation of immune responses may
promote the escape of tumor cells. It is not known whether
a site-specific suppression of rejection responses occurs in other
EBV associated malignancies.
In this study we have addressed the status of EBV specific
immunity in NPC patients by investigating the phenotype,
frequency of EBV specific T cells and capacity to mount cytotoxic
responses upon stimulation with autologous EBV carrying cells in
the blood ofnewly diagnosed NPC patients and in tumor
infiltrating lymphocytes (TILs) from a subset of the patients. We
show that efficient EBV-specific CTL responses can be reactivated
in blood lymphocytes from the majority of NPC patients, in spite
of a significant decrease in the number of circulating T
lymphocytes and in the frequency of cells recognizing LMP1
and LMP2 epitopes. LMP1 and LMP2 epitopes-specific T cells
were enriched in TILs expanded in IL-2 but t were not cytotoxic
and failed to produce IFN-c upon specific stimulation. Thus, EBV-
specific rejection responses appear to be selectively inhibited at the
tumor site in NPC.
RESULTS
EBV antibody titers, virus load and serum levels of
cytokines
Heparinized venous blood and tumor biopsies were collected from
40 untreated NPC patients at the time of first remittal to the
Nasopharyngeal Carcinoma Unit of the Cancer Center of Sun-yat
Sen University, and blood was collected from 20 healthy
volunteers. The clinical diagnosis of NPC was confirmed by
histopathology in all cases and the expression of EBER1 was
confirmed by ISH in 30 biopsies (Table 1). Previous EBV infection
was confirmed by the presence of IgG-VCA antibodies in all
patients and controls (Figure 1). IgG titers to VCA and EA were
significantly higher in patients compared to controls (P,0.001 and
P,0.005 respectively, Figure 1A and 1B) while IgA antibodies to
VCA and EA were detected in 88% and 70% of the patients,
respectively, but not in healthy EBV carriers (P,0.001).
Figure 1. EBV VCA and EA antibody titers and EBV DNA in the serum of NPC patients and healthy EBV carriers. Antibody titers to EBV VCA IgG and
IgA (A) and EA IgG and IgA (B) in the serum of healthy donors (n=20) and NPC patients (n=40); EBV DNA load (C) in healthy donors (n=20) and NPC
patients (n=24); ns= non significant.
doi:10.1371/journal.pone.0001122.g001
EBV Specific Immune Response
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..................................................................................................................................................
Gender/age HLA type NPC type
b WHO classification
c Clinical Stage
d EBV status
P1 M/30 A02,11; B4001,51 III T4N1M0 IVa +
P2 M/32 A02,33; B1501,35 III T4N2M0 IVa +
P3 M/50 A02; B13,38 III T2N1M0 II +
P4 F/58 A02,11; B13,46 III T2N2M0 III +
P5 F/40 A11,33; B44,46 III T4N0M0 IVa +
P6 M/35 A02,33; B65,58 I T4N1M0 IVa +
P7 M/30 A02; B46 III T3N2M0 III +
P8 M/33 A02,11; B60,75 III T4N2M0 IVa +
P9 M/60 A02; B13,38 III T4N3M0 IVa +
P10 M/33 A02; B46,58 III T4N1M0 IVa +
P11 M/35 A02,24;B1501 III T3N2M0 IVa +
P12 F/53 A11,26; B13,44 I T4N2M0 IVa +
P13 M/53 A02,33; B46,57 III T3N2M0 III +
P14 F/38 nd
e III T4N1M0 IVa +
P15 M/41 nd III T3N1M0 III +
P16 M/43 nd III T3N2M0 III +
P17 F/51 A02,24; B46,58 III T3N2M0 III +
P18 F/38 nd III T3N2M0 III nd
P19 M/57 A11,33; B15(62);58 III T3N2M0 III +
P20 F/50 A1133; B58,62(15) III T3N2M0 III +
P21 M/47 A02,02; B46,58 III T3N1M0 III +
P22 M/33 nd III T2N2M0 III +
P23 M/35 nd III T2N1M0 II nd
P24 M/36 A02,11; B46,1502 III T2N0M0 II +
P25 M/47 A01,11; B40(60),54 III T2N1M0 II +
P26 M/46 A24;B40(60) III T3N2M0 III nd
P27 F/72 nd III T3N2M0 IVa +
P28 M/46 nd III T3N2M0 III nd
P29 M/34 nd III T2N1M1 IVb nd
P30 M/76 A02,11; B13,46 III T3N1M0 III nd
P31 M/38 A02,02; B38,44 III T4N0M0 IVa +
P32 M/57 nd III T4N0M0 IVa nd
P33 M/51 A11,33; B38,58 III T2N2M0 III +
P34 M/47 A02,24; B38,40(60) III T3N2M0 III nd
P35 M/53 A02,24;B15,46 III T2N2M0 III +
P36 M/33 A02,11; B46 III T2N2M0 II +
P37 M/78 A02,33;B46,58 III T2N3M0 III +
P38 M/30 A02,11; B15(75),38 III T4N4M4 IVb +
P39 M/56 A02,24; B40(61),54 III T2N3M0 IVa nd
P40 M/30 A02,11;B15(76),40(60) I T2N2M0 III nd
N1 M/19 nd - - - 2
N2 F/20 nd - - - 2
N3 M/22 nd - - - 2
N4 M/19 nd - - - 2
N5 F/21 A02,11; B13,75(15) - - - 2
N6 M/22 A02,11;B46 -
N7 M/23 A02,33; B46,58 - - - 2
N8 M/24 A26,30;B13,40(61) - - - 2
N9 M/22 A11; B39,53 - - - 2
N10 M/22 A33; B58 - - - 2
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EBV Specific Immune Response
PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1122The presence of EBV DNA was investigated by real time
quantitative PCR in the serum of 24 NPC patients and 20 controls
(Figure 2B). Between 10
3 to .10
6 genome copy/ml serum were
detected in all patients, while less than 10
4 copies/ml were
detected only in 2 out of 20 healthy donors (P,0.01).
The serum levels of Th1 (IFN-c, IL-2, TNF-a) and Th2 (IL-4,
IL-6, IL-10) cytokines were analyzed in 27 patients and 19
controls. The serum levels of all cytokines were below the
sensitivity of the CBA in all but one healthy control where small
amounts of IL-2 were detected, while IFN-c (3.263.0 pg/ml), IL-6
(2.863.0 pg/ml) and IL-10 (1.561.3 pg/ml) were detected in the
serum of the majority of the patients (Table 2). Low levels of
TNFa, IL-2 and IL-4 were also detected in few patients.
T cell phenotype and frequency of EBV specific T
cells in PBMCs
To evaluate the distribution of lymphocyte subsets, the expression of
surface markers specific for T cells: CD3, CD4, CD8; NK cells:
CD16; naı ¨ve, memory and activated T cells: CD45RO, CD45RA
and CD25,wasdetectedbyimmunoflourescence stainingand FACS
analysis in PBMCs from all patients and controls (Figure 2). The
percentage of CD3
+,C D 3
+CD8
+ and CD3
+CD4
+ T cells were
significantlydecreasedinthepatients(56612.5, 2168.8and2669.5
compared to 6869.3, 2766.5 and 34610.7, respectively), and this
was companied by a relative increase of CD3
2CD16
+ NK cells
(28.1611.1 compared to 2269.5). The patients also showed
Figure 2. Immunophenotype of PBMCs from healthy donors and NPC patients. Surface markers analysis was performed by directly
immunofluorescence labeling and FACS analysis in PBMCs from healthy donors (n=20) and NPC patients (n=40). * P,0.01
doi:10.1371/journal.pone.0001122.g002
Table 1. cont.
..................................................................................................................................................
Gender/age HLA type NPC type
b WHO classification
c Clinical Stage
d EBV status
N11 F/22 nd - - - 2
N12 F/21 A01,11; B15(63),15(75) - - - 2
N13 M/23 A02,11;B13,51 - - - 2
N14 F/24 A02,33; B46,58 - - - 2
N15 F/23 A02;B13,52 - - - 2
N16 F/23 A02;B15,40 - - - 2
N17 M/25 A11,33; B40(60),58 - - - 2
N18 M/53 A11,24;B4001 - - - 2
N19 M/57 A02,11;B46,56 - - - 2
N20 M/35 A02,11;N13,46 - - - 2
aP=NPC patient; N=healthy donors.
bHistological type: I=differentiated keratinizing squamous cell carcinoma (SCC); II=differentiated non-keratinizing carcinoma; III=undifferentiated carcinoma (UCNT).
cTNM stage according to WHO UICC-AJCC 1997 standards (International Union Against Cancer/American Joint Committee on Cancer).
dClinical stage: Stage I=T1N0M0; Stage II=T2N0-1M0; T0-1N1M0; Stage III=T3N0-2M0 or T0-3N2M0; Stage IVa=T4N0-3M0; T0-4N3M0 or Stage IVb=all T and all N plus
M1.
end=not done.
doi:10.1371/journal.pone.0001122.t001
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EBV Specific Immune Response
PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1122a significant decrease in CD3
+CD45RA
+ and CD4
+CD25 naı ¨ve T
cells (2469.0 and (25.468.5 compared to 39612.2 and 37.8611.5,
respectively) while there was no difference in the percentage of T
cells expressing a CD45RO
+CD3
+, memory phenotype (26.167.6
and 28.166.8, respectively). A significantly higher percentage of
CD4
+CD25
+ activated T lymphocytes was detected in the patients
compared to healthy donors (764.9 and 361.6, respectively)
The presence of CD3
+CD8
high T cell able to recognize epitopes
in LMP1 (YLQ, YLL, ALL) and LMP2 (LLW, CLG, GLG, FLY)
was investigated by tetramer staining in PBMCs from 9 HLA-A2
positive patients and 7 controls (Figure 3 and Supplementary
Information Figure S2). The percentage of tetramer positive cells
was generally lower in the patients and the differences were
statistically significant as assayed by Mann-Whitney U test
(P,0.05) for 2 out of 3 LMP1 epitopes (YLQ: 0.22 and 0.34,
ALL: 0.25 and 0.64, respectively), and 3 out of 4 LMP2 epitopes
(LLW: 0.26 and 0.64, GLG: 0.45 and 0.67, FLY: 0.27 and 1.03,
respectively). In line within the observation that LMP2 contains
several immunodominant HLA-A2 restricted epitopes [19], the
PBMCs of healthy donors showed higher frequencies of cells
stained with LMP2 compared with LMP1 tetramers (P=0.003,
Mann-Whitney U test), but this difference were not seen in
PBMCs from NPC patient.
Reactivation of EBV-specific CTLs and LMP1 and
LMP2 tetramer positive cells
In order to assess the presence of circulating EBV specific CTLs
precursors, PBMCs from 15 NPC patients and 8 controls were
stimulated with the autologous LCL and the cytotoxic activity of
the cultures was tested against a panel of EBV positive and
negative targets. Efficient expansion of CD3
+CD8
+ T cells
expressing CD45RO
+ was achieved in all cases (not shown).
Three patterns of cytotoxicity were recognized based on
differential killing of EBV
+ or EBV
2 targets (Figure 4A and
Table 3): Pattern I: EBV specific cytotoxicity, characterized by
efficient lysis ($25% at 10:1 R:S ratio) of the autologous and
allogenic HLA class I matched LCLs and no lysis of autologous
PHA blast and HLA class I mismatched targets, Pattern II: LAK-
type cytotoxicity, characterized by equal lysis of HLA class I
matched and mismatched LCLs and Pattern III: no cytotoxicity,
where the specific lysis against all targets was #10% at 10:1 R:S
ratio. EBV specific cytotoxicity could be reactivated in 8 out 10
controls (80%) and in a slightly lower proportion of patients (10
out of 15, 66%) while LAK-type response was obtained in 2
donors (20%) and 3 patients (20%) and cytotoxicity was not
detected in the cultures from 2 patients (13%) (Table 3), The lytic
capacity of auto-LCL stimulated cultures was also supported by
the presence of CD3
+CD107a
+ T cells in cultures incubated for
4 hrs with different targets cells or peptides (Supplementary
Information Table S1). A Pattern I cytotoxicity was associated
with efficient lysis of autologous primary tumor cells in the CTL
cultures derived from 2 NPC patients (Figure 4B).
Figure 3. Frequency of LMP1 and LMP2 epitope- specific T cells in PBMCs from healthy donors and NPC patients. The frequency of T cells specific
for HLA A2 restricted on LMP1 and LMP2 was detected by EBV tetramer staining and FACS analysis in freshly isolated PBMCs from healthy donors
(n=7) and NPC patients (n=9). The number of tetramer positive cells in 100 lymphocytes are shown in the figure.
doi:10.1371/journal.pone.0001122.g003
Table 2. Serum levels of Th1 and Th2 cytokines.
......................................................................
Cytokine Healthy donors NPC Patients
Positive/
Total (%)
Mean
pg/ml
Positive/
Total (%)
Mean
pg/ml
IFN-c 0/19 (0) 0 19/27 (70) 3.2*
TNF-a 0/19 (0) 0 9/27 (33) 0.6
IL-2 1/19 (5) 0.2 4/27 (15) 0.4
IL-4 0/19 (0) 0 3/27 (11) 0.2
IL-6 0/19 (0) 0 21/27 (78) 2.8*
IL-10 0/19 (0) 0 20/27 (74) 1.5*
*Significant different from healthy donors (P,0.0001).
doi:10.1371/journal.pone.0001122.t002
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1122Tetramer staining was performed to investigate the frequency of
T cells specific for LMP1 and LMP2 epitopes in CTL cultures
from 9 HLA-A2 positive patients and 4 controls (Figure 5, Table 4).
As observed in PBMCs, the overall frequency of T cells stained
with the LMP1 and LMP2 tetramers remained lower in the
patients compared to controls and the differences were statistically
significant as assayed by Mann-Whitney U test (P,0.05) for 1 out
of 3 LMP1 epitopes (YLL 0.40 and 1.08, respectively), and 2 out of
4 LMP2 epitopes (LLW 0.33 and 1.41, CLG 0.83 and 3.97,
respectively) although the frequency of tetramer positive cells was
increased following LCL stimulation in all cases (Figure 5). The
efficiency of the response against the various epitopes appeared to
be somewhat different. Thus, while the CLG and FLY epitopes in
LMP2 were clearly preferred in the healthy donors, T cells
recognizing the ALL and YLL epitopes in LMP1 and CLG
epitope in LMP2 were preferentially expanded in the patients and
the response to ALL and YLL was stronger in NPC patients
compared to healthy EBV carriers (Table 4, and Supplementary
Information Figures S2 and S3, Tables S1 and S2).
Phenotypic and functional characterization of TILs
In order to investigate whether T cells capable of recognizing the
malignant cells are present in the tumor, TILs were isolated from
25 NPC biopsies and then expand in medium containing low
doses of IL-2 without additional stimulation until the cell number
was sufficient for analysis (Figure 6). Similar to LCL-stimulated
cultures the TILs contained a high proportion of cells expressing
a CD45RO
+CD3
+ memory cell and CD25
+ activated T cell
phenotype while CD45RA
+CD3
+ and CD4
+CD25
2 naı ¨ve T cells
and CD3
2CD16
+ NK cell were strongly decreased compared to
PBMCs (compare Figure 2 and Figure 6A). A relative increase of
CD3
+CD4
+ cells and decrease of CD3
+CD8
+ cells was also
observed compared to LCL-stimulated cultures, but the differ-
ences were not significant.
The presence of T cells specific for LMP1 and LMP2 epitope
was investigated in TILs from 6 HLA-A2 positive patients
(Figure 6B). The frequency of T cells stained by the LMP1 and
LMP2 tetramers was higher compared to PBMCs in all cases,
suggesting that T cells specific for these epitopes are enriched in
the tumor. Although the TILs resembled in many respects LCL-
activated cultures, comparison of paired cultures revealed
a different representation T-cells specific for LMP1 and LMP2
epitopes. While T cells recognizing YLL, ALL and CLG epitopes
were preferentially expanded upon LCL-stimulation, T cells
specific for the YLQ, LLW and GLG epitopes were preferentially
enriched in TILs (Table 4).
The presence of EBV specific cytotoxic activity was investigated
in 10 TIL cultures (Figure 7). The levels of specific lysis against all
targets tested were below 10% at 10:1 E:T ratio in every cases.
The lack of cytotoxic capacity was also confirmed by CD107a
staining after stimulated by different targets cells or peptides
(Supplementary Information Figure S4 and Table S3). To further
investigate whether EBV specific responses could be detected by
more sensitive assays, six of the TIL cultures were tested for their
capacity to produce IFNc in response to stimulation with
autologous LCLs by EILSPOT assay or intracellular staining
(Table 5 and Supplementary Information Table S4). In line with
the efficient reactivation of EBV-specific cytotoxicity, high
frequencies of EBV-specific T lymphocytes were detected by
ELISPOT assays in the PBMCs from patients and controls while
Figure 4. Cytotoxic activity of auto-LCL activated cultures from PBMCs of NPC patients. Polyclonal CTL cultures were test for cytotoxic activity
against a panel of targets including the autologous EBV transformed LCL, PHA blasts, allogenic HLA class I matched or mismatched LCL. A.
Representative experiments illustrating three pattern of cytotoxic activity. Pattern I: Lysis of the auto-LCL $25% and HLA class I mismatched LCL
#10%; Pattern II: lysis to both HLA class I matched and mismatched LCL; Pattern III: less than 10% lysis against autologous or allogenic EBV positive or
negative targets B. EBV-specific CTL cultures from NPC patients lysed freshly isolated autologous NPC tumor cells. Representative
51Cr release assays
performed with CTL cultures from two NPC patients are shown in the figure.
doi:10.1371/journal.pone.0001122.g004
EBV Specific Immune Response
PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1122the frequency of IFNc spot forming cells was significantly lower in
TILs. Similar results were obtained when IFNc production was
assessed by intracellular staining. Intracellular staining of cells
treated with PMA and inomycin confirmed that the TILs were
able to produce IFNc at levels comparable to those observed in
LCL-stimulated cultures, whereas the response to autologous
LCLs was only marginally different from that induced by
stimulation with autologous PHA blast or mismatched LCLs.
DISCUSSION
Conventional treatment for NPC frequently fails and is often
accompanied by severe long-term side effects [20]. This, together
with the regular association of undifferentiated NPC with EBV
infection, and the expression of immunogenic viral antigens in the
tumor cells, has motivated strong efforts to develop strategies of
immune intervention that could complement or even substitute
current therapeutic regimens (reviewed in [21]. The success of this
endeavor is tied to a better understanding of the reasons for the
failure of endogenous immunity.
Our study performed on a relatively large number of newly
diagnosed NPC patients confirms previous observations indicating
that the tumor carrier status is associated with an imbalance in the
control of EBV infection [22]. The increased antibody titers to
structural antigens and the presence of IgA antibodies to VCA and
EA and viral DNA in the serum (Figure 1) suggest that productive
infection occursat mucosal sites. This, together with the tumor mass,
is likely to cause inflammatory responses that are revealed by the
high serum levels of both Th1 and Th2 cytokines (Table 2). Ongoing
inflammation may also explain the relative decrease of circulating T
lymphocytes and the presence of few T cells expressing activation
marker (Figure 3) since activated T cells express adhesion molecules
and chemokine receptors that can promote homing to the site of
inflammation. The finding that EBV specific CTLs could be
reactivated from the blood inthe majority of NPC patients (Figure 4)
is also in line with previous reports [23,24] and confirms that overall
preserved immunocompetence of the patients. Although EBV
specific responses were not detected in approximately one third of
the patients (Table 3), this failure did not appear tocorrelate with the
clinical stage of the disease and may due to technical limitation,
possibly associated with the use of LCLs carrying a laboratory strain
of EBV rather than the endogenous virus. It is noteworthy that
although the average age of NPC patients was higher than that of
healthycontrols,thestrongestCTLresponseswereactuallyobserved
in some of the patients. It remains unclear what causes, in the face of
persistent T cell response, the impaired control of latent infection
reflected by the high antibody titers and presence of EBV DNA in
the serum. While viral DNA may be released from the tumor mass
due to necrosis, the malignant cells are not a likely source of EBV
structural antigens since in the infection is latent in the tumor
[25,26]. Conceivably, EBV reactivation could be triggered by
cytokines released at sites of inflammation in the mucosa surround-
ing the tumor. It remains to be seen whether normal levels T cells
specific for EBV lytic antigens are present and functionally
competent in the patients.
Our analysis of epitope choice was focused on HLA-A2 restricted
epitopes derived from LMP1 and LMP2 since this HLA class I allele
was shown to be associated with increased risk to develop NPC in
Chinese [27] and, being expressed in the malignant cells, these viral
antigens are possible targets of anti-tumor responses. Interestingly,
we found that the frequency of T cells capable of recognizing seven
different epitopes in these proteins was significantly decreased in the
blood of NPC patients compared to healthy donors. The relatively
low representation of LMP1 and LMP2 specific T cells was
maintained also after stimulation of the PBMCs with autologous
LCLs in spite of efficient activation cytotoxic responses, indicating
that LMP1 and LMP2 are not dominant targets of EBV specific
CTLs NPC patients. This is in line with previous reports showing
that, as in healthy EBV carriers, to response of PBMCs from NPC
patients to standard LCL-based reactivation protocols is dominated
by CTLs directed to epitopes inthe nuclear protein EBNA3, 4 and 6
[23,28]. While the preferential reactivation of EBNA-reactive cells
may be driven by the epitope repertoire presented by LCL cells, our
finding that T cells recognizing LMP1 and LMP2 epitopes are
differently expanded in the patients compared to controls indicates
that tumor carriage may be associated a different choice of epitopes.
Thus, while is agreement with previous reports [29] two LMP2
epitopes, CLG and FLY, dominated the response in healthy donors,
two LMP1 epitopes, YLL and ALL, appeared to be preferentially
expanded in NPC patients. This may reflect differences in the
functional status of circulating CTL precursors. Although the
number of patient is too small to warrant firm conclusions, this
observation could have important implications for the choice of
antigens and antigen presenting cells in immunotherapy settings.
Analyzing EBV-specific responses in NPC tumor biopsy
material, we found that TILs expanded for short time in IL-2 in
the absence of exogenous stimuli were unable to lyse autologous
EBV infected targets and only a minor proportion of the cells
produced IFN-c upon stimulation with the autologous LCL
although the majority could be triggered to do so upon stimulation
Table 3. Patterns of cytotoxicity induced by stimulation of
PBMCs with the autologous LCL.
......................................................................
Autologous LCL
a
Autologous
PHA blast
HLA Mismatched
LCL Pattern
b
P1 +++ 22 I
P5 +++ 22 I
P13 ++ 2 + II
P17 ++ 22 I
P19 ++ 22 I
P20 +++ 22 I
P30 ++ 22 I
P31 + 22 II
P32 ++ 22 I
P33 ++ 2 + II
P34 + 22 II
P35 ++ 22 I
P36 + 22 II
P37 + 2 + II
P40 22 2 III
N5 ++ 22 I
N6 ++ 22 I
N14 ++ 22 I
N16 ++ 22 I
N15 ++ 22 I
N12 ++ 22 I
N18 + 2 ++ II
N20 + 2 + II
a2=Specific lysis ,10%; +=Specific lysis 10–25%; ++=Specific lysis 25–50%;
+++=Specific lysis .50%.
bScore: Pattern I=Specific lysis; Pattern II=non-specific lysis; Pattern III=no
lysis.
doi:10.1371/journal.pone.0001122.t003
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restimulation protocols and performed our analysis soon after
isolation in order to preserve, within the limits of what is feasible
given the very small amount of starting material, the character-
istics of the original TIL population. It is noteworthy that,
although functionally inactive, the expanded TILs expressed an
activated memory T cell phenotype similar to that of LCL-
stimulated PBMCs and were enriched in T cells specific for all the
LMP1 and LMP2 epitopes tested. Thus, the relative decrease of
LMP1 and LMP2 specific cells observed in the periphery does not
appear to reflect a selective loss of these cells but rather their
preferential homing to the tumor. Previous work on NPC biopsy
demonstrated that CTL precursors specific for various EBNAs can
be reactivated upon stimulation of TILs with autologous LCLs but
did not detect any responses to LMP2 or any other NPC-
associated viral protein [23]. This was taken to suggest that LMP2-
specific responses may be excluded from the tumor site. Our
findings offer another explanation, namely that, although
appropriate CTL precursors reach the tumor, they are selectively
rendered nonfunctional at this location.
Work on tumor biopsies from HD patients have earlier
suggested that EBV-specific CTL responses may be inhibited in
the EBV positive tumors [18]. Similar to NPC, the malignant
Reed-Sternberg cells of HD express EBV latency II and it is
therefore conceivable that one or more of the viral proteins that
characterize this latency program may be involved in the local
suppression of EBV-specific immunity. LMP1 is a prime candidate
due to its capacity to induce constitutive activation of NF-kB and
the production of cytokines such as IL-10 that is known to suppress
cellular immune responses [30,31,32,33,34,35]. In line with this
possibility we have found significant amount of IL-10 in the serum
of 20 out of 27 NPC patients (Table 2). LMP1 may also have
a more direct effect on the regulation of EBV specific responses
since two LMP1 peptides with strong homology to an immuno-
suppressive peptide found in the retrovirus-encoded transmem-
brane protein p15E were shown to strongly inhibit CTL and
natural killer (NK) cell activity in vitro [36]. It is noteworthy that
the TIL cultures were enriched in CD4
+ cells and a significant
proportion of these cells also expressed CD25. CD4
+CD25
+ cells
expressing the forkhead box (Fox)p3 transcription factor, also
known as Treg, are a suppressor T cell population that regulates
a variety of immune responses. Recent studies demonstrate that
elevated proportions of Treg cells are present in various types of
cancers and suppress anti-tumor immunity [37,38]. Importantly,
tumor-specific Treg cells were shown to inhibit immune responses
only when exposed to antigens presented by tumor cells
[39,40,41]. It remains to be seen whether the LMP1 or other
viral proteins expressed in NPC may be directly responsible for the
activation of T-cells with the capacity to suppress virus-specific
immune responses at the tumor site.
Our findings have interesting implications for current efforts to
develop therapeutic strategies for NPC based on selective boosting
of endogenous immunity or adoptive transfer of CTLs. In spite of
a clear imbalance in the control of EBV infection, the majority of
NPC patients are capable of mounting efficient responses to LCLs in
Table 4. A activation of EBV epitope specific T cells in auto-
LCL stimulated PBMCs (ALSC) and TILs.
......................................................................
Increase of epitope specific T cells
a
YLQ YLL ALL LLW CLG GLG FLY
Healthy ALSC/PBMC (n=3) 3.9 3.8 2.5 4 11.7 3.2 15.7
Patients ALSC/PBMC (n=4) 1.4 4.2 3.5 1.6 4.5 1.3 2.5
Patients TIL/PBMC (n=3) 4.2 3.8 1.6 2.6 3 4.7 2.6
aFold increased was calculated as mean % tetramer positive cells in ALSC or
TILs/ mean % tetramer positive cells from PBMCs. Frequency of T cells
recognizing LMP1 or LMP2 epitopes was determined by tetramer staining in
paired samples derived form the donors.
doi:10.1371/journal.pone.0001122.t004
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Figure 5. Frequency of LMP1 and LMP2 epitope- specific T cells in auto-LCL stimulated cultures from healthy donors and NPC patients. The
frequency of T cells specific for HLA A2 restricted epitopes in LMP1 and LMP2 was detected by EBV tetramer staining and FACS analysis in auto-LCL
stimulated cultures from healthy donors (n=4) and NPC patients (n=9).
doi:10.1371/journal.pone.0001122.g005
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However, the different antigen choice observed in NPC patients and
the finding that EBV-specific T cells may be inactivated in the
tumor, possibly due to exposure to an antigenic repertoire that
triggers Treg responses, suggest that the outcome of immunization
strategies will be strongly dependent on the choice of antigens and
antigen presenting cells. Most importantly, a choice based on the
specificity and strength of the responses induced by LCL stimulation
is probably not optimal since the tumor cells may present a different
set of antigenic peptides and some of the presented epitopes may
suppress rather than enhance the anti-tumor effect. Adoptive
transfer of CTLs may hold a better chance of success since studies
of NPC cell lines indicate that the malignant cells are capable of
processing endogenously antigens and at least some of the epitopes
are recognized by HLA class I-restricted CTL activated by the
currently used reactivation protocols [23,24,42]. Our finding that
LMP1 and LMP2 specific T cells are enriched in TILs suggests that
in vitro activated CTLs may also traffic to the tumor but it remains to
be determined whether and for how long these cells will remain
functional at the tumor site. Thus, the development of means to
controltheactivityofTregsshouldbecomeanimportantfocusinthe
establishment of effective strategies of immune intervention in NPC
and, by inference, other EBV associated malignancies expressing
latency II.
MATERIALS AND METHODS
Sample collection
Heparinized venous blood and tumor biopsies were collected from
40 untreated primary nasopharyngeal carcinoma (NPC) patients
at the time of first remittal to the Nasopharyngeal Carcinoma Unit
of the Cancer Center of Sun-yat Sen University. Twenty healthy
donors were students and coworkers of the Cancer Center, All
patients and healthy donors were South Chinese living in
Guangdong province for 2–3 generation. The Ethical Committee
of the Sun-yat Sen University Cancer Center approved the study
and full consent was obtained from all patients and healthy donors.
The NPC histological type and clinical stage were determined
according to the UICC/AJCC 1997 classification [43]. A
summary of the clinic information, HLA type and EBV status of
the patients and controls is shown in Table 1.
Study design
Peripheral blood mononuclear cells (PBMCs) were isolated from
30 ml heparinized blood, by Ficoll/Isopaque gradient fractionation
and monocytes were depleted by plastic adherence. 10
7 PBMCs
were used for EBV infection, PHA activation, phenotype analysis
and EBV tetramer staining. The remaining cells were cryopreserved
Figure 6. Immunophenotype of LCL stimulated cultures and TILs from NPC patients (A). Surface markers were detected by directly
immunofluorescence and FACS analysis in LCL-stimulated cultures (n=13) and tumor infiltrating lymphocyte (n=25) expanded for 1 to 4 weeks in IL-
2 medium without antigen stimulation. A relative decrease of CD8+ cells and increase of CD4+ cells was observed in TILs compared to LCL-stimulated
cultures; both cultures showed high percentage of CD3+CD45RO+ and CD4+CD25+ cells. Frequency of LMP1 and LMP2 epitope-specific T cells in
auto-LCL stimulated cultures and TILs from NPC patients (B). LMP1 and LMP2 epitopes specific T cells were detected by EBV tetramer staining and
FACS analysis in autologous LCL-stimulated PBMCs (n=9) and TILs (n=6) from NPC patients.
doi:10.1371/journal.pone.0001122.g006
Figure 7. Cytotoxic activity of LCL-stimulated cultures and TILs from
NPC patients. The mean 6SD percentage lysis at 10:1 E:T ratio of LCL-
stimulated cultures (n=15) and TILs (n=9) from NPC patients is shown
in the figure.
doi:10.1371/journal.pone.0001122.g007
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became available. Serum samples were collected for determination
of EBV specific antibodies, EBV DNA load, and cytokines levels.
The tumor biopsies were divided into small portions for histopa-
thology investigation and, when possible, analysis of EBV status by
EBER1 in situ hybridization. When available, one portion was used
for isolation of tumor infiltrating lymphocytes and the remaining
portion was used to set up primary tumor cell cultures.
In situ hybridization (ISH)
Paraffin embedded NPC sections were subjected to antigen retrieval
by dewaxing for 15 min at 95uC in 0.01 M sodium citrate buffer in
a steam cooker. EBER expression was detected by ISH using the
Epstein-Barr Virus Probe ISH Kit (Novocastra Laboratories Ltd,
Newcastle, UK) according to the instruction of the manufacturer.
Serum EBV antibody titers, DNA load and cytokine
levels
IgG and IgA antibody titers against the EBV virus capsid antigen
(VCA) and early antigen (EA) were detected using a commercial
enzyme-labeling immunostaining assay detection kit (Zhongshan
Biotechnology Company, Tianjin, China) according to the
instruction of manufacturer. EBV DNA load was determined by
real time quantitative PCR in DNA extracted from 250 ml serum
with the QIAamp Blood Kit (Qiagen, Hilden, Germany) using the
probe W-67T derived from the BamHI-W region of the EBV
genome. The procedures for real-time quantitative PCR and
reaction set-up were carried out as described previously [44]. Fifty
ml of serum were analyzed for cytokine content, using the human
Th1/Th2 cytokine Cytometric Bead Array Kit (BD-Bioscience/
Pharmingen, San Diego, CA) as described [45]. Fluorescence was
detected using a FACS Aria
TM and the data were analyzed using
the CBA software (BD Bioscience).
Isolation of tumor infiltrating lymphocytes (TILs)
and culture of primary tumor cells
The NPC biopsies were minced and digested with 100 mg/ml
Collagenase IV (Sigma, St. Louis, USA) for 2–3 h at 37uC. TILs
were isolated from the single cell suspension by Ficoll-Hypaque
gradient centrifugation (Zhongshan biocompany, Tianjin, China),
and 2610
6 cells were cultured for 1 to 4 weeks in RPMI 1640
supplemented with antibiotics, 10% fetal calf serum complete
(FCS, GIBO), and 20 IU/ml IL-2 (R&D Systems Inc, Minnea-
polis, USA) in 24-well tissue culture plates. When available, a small
aliquot of the NPC tissues was finely minced and the fragments
were placed in a 25 cm
2 tissue culture flask coated with type I
collagen (Sigma). The adherent cells were maintained in
Keratinocyte-SFC medium supplemented with 20 mM L-gluta-
mine, 5 ng/ml human recombinant epidermal growth factor and
50 mg/ml bovine pituitary extract (Invitrogen). The NPC primary
culture cells were expansion in vitro for 5 to 8 generations and
then frozen for later use. The phenotype of the NPC primary
culture cells is shown in Supplementary Information Figure S1.
Flow cytometry and tetramer staining
PerCP, FITC or PE-conjugated mouse monoclonal antibodies
(MAbs) to CD3 (Clone UCHT1), CD4 (Clone RPA-T4), CD8
(Clone RPA-T8), CD16 (Clone 3G8), CD45RA (Clone HI100),
(Clone UCHL1) from BD Pharmingen Company (San Jose, CA,
USA) and FITC-conjugated anti-human CD4 (Clone RPA-T4)
and PE-conjugated anti-human CD25 (BC96) from eBioscience
(San Diego, CA, USA) were used for surface markers analysis. The
cells were incubated with appropriate fluorochrome conjugated
MAb at 4uC for 30 min, followed by three washes in phosphate-
buffered saline (PBS). Fluorescence was detected with a FACS
Aria
TM and data was analyzed with FACS Diva software (BD
Biosciences).
The frequency of T cell specific for HLA-A2 restricted epitopes
was analyzed by staining with HLA-A2 tetramers assembled with
synthetic peptides from LMP1: YLQQNWWTL, YLLEMLWRL,
ALLVLYSFA and LMP2: CLGGLLTMV, FLYALALLL,
GLGTLGAAI, LLW TLVVLL (Guangzhou Taimo Corporation,
Guangzhou, China). Aliquots of 0.5–1610
6 cells were incubated at
4uC for 30 minutes in PBS containing 1% FCS and 1 mgo f
phycoerythrin (PE)–labeled tetramers. The samples were co-stained
with anti-CD8-FITC and anti-CD3-PerCP MAbs followed by
fixationin0.5%paraformaldehyde[46].At least10
5cellspersample
were analyzed.
Table 5. Production of IFNc by TILs.
..................................................................................................................................................
IFN-c producing cells
ELISPOT
a (%) Intracellular staining
b
Control Auto LCL Control PMA inomycin Auto LCL PHA blast
P3 2 2 0.3 32.8 0.7 0.2
P4 - - 0.5 81.2 0.7 0.5
P6 16 - - - -
P10 24 - - - -
P24 3 46 0.2 69.2 0.5 0.1
P31 - - 0.2 19.8 0.3 0.3
Patient PBMC (n=3) 21 6 6 - - - -
Patient ASLC (n=11) - - 1.2 40.6 5.6 1.7
Healthy PBMC (n=3) 32 3 0 - - - -
Healthy ASLC (n=8) - - 1.2 36 6.1 1.2
aNumber of spot-forming cells (SFC)/10
6.
bPercentage of IFN-c producing cell detected by intracellular staining.
doi:10.1371/journal.pone.0001122.t005
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cultures
LCLs weregenerated byEBV infection of 2610
6 PBMCs with spent
supernatant from the B95-8 virus producing cell line [47], in the
presence of 1 mg/ml cyclosporin A (Sigma). Cryopreserved PBMCs
were thawed and aliquots of 3610
6 cells were stimulated in 24 well
plates with irradiated (4000 Rads) LCL cells at 40:1 responder:-
stimulator (R:S) ratio. After 7 days, viable cells were re-stimulated
under the same conditions and, 3 days later, the cells were expanded
in complete medium containing 10 UI/ml IL-2 (R&D Systems Inc).
The cultureswererestimulatedweekly.Forgeneration of PHA blasts
PBMCs were stimulated with 1 mg/ml PHA-L (Sigma) for 3 days
and expanded in IL-2 containing medium. The HLA type was
determined by sequence specific primer (SSP)-PCR in the
Guangzhou Organ Transplant and Tissue Typing Center.
Cytotoxicity assay
Cytotoxic activity was evaluated in standard 4h
51Cr release
assays, as previously described [48]. The targets panel included
autologous LCLs and PHA blasts, allogeneic HLA class I
mismatched or, when available, single HLA class I allele matched
LCLs and autologous primary NPC cells. All assays were run in
triplicate and the results are presented as the mean6SD.
Intracellular cytokine and CD107a staining
Five610
5 cells were stimulated with PMA/inomycin (0.5–1 mg/ml),
auto-LCL at 3:1 R:S ratio or EBV peptide (20 mg/ml) in 200 mlo f
complete RPMI 1640 medium in 96-well round tissue culture plate,
in the presence of PE-conjugated mouse anti-human CD107a
antibody(Clone H4A3 ) and GolgiPlug (BD Phar-Mingen, San
Diego, CA) for 4 h at 37uC in dark. Intracellular cytokinestaining was
performed using the Cytofix/Cytoperm Plus kit (BD PharMingen).
ELISPOT assay
ELISPOT assays were performed as previously described [49].
Five 610
5 cells were plated on Multi-Screen Immobilon-P
filtration plates (Millipore, Bedford, MA) pre-coated with IFN-c-
specific mAbs (Ucytech Biosciences, Netherlands) and then
incubated overnight with the auto-LCL, HLA class I matched
LCL at 10:1 R:S, or 20 mg/ml of synthetic EBV peptides. The
IFN-c producing cells were detected as red spots by using a human
IFNc ELISPOT kit (U-CyTech Biosciences Company, Nether-
lands) and counted with the ImmunospotTM Acessories software
(Cellular Technology Ltd, Carnegie Avenue, Cleveland, USA). All
assays were performed in duplicate. Spontaneous IFNc production
was detected by omitting the stimulation and maximal activity was
measured by stimulation with 10 mg/ml PHA.
Statistical analysis
Statistical analysis was performed with the SSPS 13.0 software
package (SPSS Inc, Chicago, USA), using Chi-square test, t student
test, or Mann-Whitney U test, with level of significance set at P,0.05.
SUPPORTING INFORMATION
Table S1
Found at: doi:10.1371/journal.pone.0001122.s001 (0.06 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0001122.s002 (0.08 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0001122.s003 (3.18 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0001122.s004 (0.03 MB
DOC)
Figure S1 Characteristics of NPC primary culture cells.
Morphology of NPC primary culture cells under light microscope
(A and B). Keratin staining (C). EBERs in situ hybridization in
NPC primary cells (C). Negative control for EBERs staining in
normal nasopharyngeal epithelia (D)
Found at: doi:10.1371/journal.pone.0001122.s005 (3.45 MB
DOC)
Figure S2 The frequency of T cells specific for HLA-A2
restriction epitopes in EBV LMP1 and LMP2 in HLA-A2
positive NPC patient and healthy donor. The frequencies of
tetramer positive cells in CD3+CD8high PBMCs and TILs
from NPC patient P24, and in PBMCs and auto-LCL
stimulated PBMCs from healthy donor N16 are shown in this
figure.
Found at: doi:10.1371/journal.pone.0001122.s006 (3.27 MB
TIF)
Figure S3 Cytotoxicity analysis of auto-LCL stimulated PBMCs
from NPC patient 1. Polyclonal CTL cultures were tested for
cytotoxic activity against autologous PHA blasts loaded with
LMP1 or LMP2 peptides in 4 hrs 51Cr release assays(A); or
stimulated with LMP1 or LMP2 peptides for 4 hrs in round 96-
well tissue culture plate followed by intracellular staining for
CD107a and IFN-c(B).
Found at: doi:10.1371/journal.pone.0001122.s007 (3.18 MB
TIF)
Figure S4 Cytotoxicity analysis of TILs from NPC patient 31.
Tumor infiltrating lymphocyte (P31) expanded for 1 to 4 weeks in
IL-2 medium without antigen stimulation, were tested for
cytotoxic activity against autologous PHA blasts loaded with
LMP1 or LMP2 peptides in 4 hrs 51Cr release assays (A); or co-
cultured with different targets cells (E:T=10:1) for 4 hrs in round
96-well tissue culture plate followed by intracellular staining for
CD107a and IFN-c(B).
Found at: doi:10.1371/journal.pone.0001122.s008 (3.22 MB
TIF)
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